Advertisement

Association Between Buprenorphine for Opioid Use Disorder and Mortality Risk

      Introduction

      Veterans with opioid use disorder have an increased risk of suicide and overdose compared with the general population. Buprenorphine, a U.S. Food and Drug Administration–approved medication to treat opioid use disorder, has shown benefits, including decreased risk of illicit drug use and overdose. This study assesses the mortality outcomes with buprenorphine pharmacotherapy among Veterans up to 5 years from treatment initiation.

      Methods

      This was a retrospective cohort study of Veterans receiving buprenorphine (2008–2017) across any Veterans Health Administration facility. Buprenorphine pharmacotherapy was evaluated as a time-varying covariate. The primary outcome was death up to 5 years from treatment initiation by suicide and overdose combined; secondary outcomes included suicide, overdose, opioid-specific overdose, and all-cause death. Secondary analyses included evaluating the risk of mortality in recent discontinuation and effect modification by select characteristics. All analyses were conducted in 2020.

      Results

      Veterans who were not receiving buprenorphine were 4.33 (adjusted hazard ratio; 95% CI=3.60, 5.21) times more likely to die by suicide/overdose than those receiving buprenorphine pharmacotherapy on any given day, with similar protective associations with treatment across secondary outcomes. The risk of suicide/overdose was highest 8–14 days from treatment discontinuation (adjusted hazard ratio=6.54, 95% CI=4.32, 9.91) than in currently receiving buprenorphine pharmacotherapy. There was no evidence of effect modification by the selected covariates.

      Conclusions

      Mortality risk was greater among Veterans who were not receiving buprenorphine pharmacotherapy than among those who were. Providers should consider whether buprenorphine pharmacotherapy, either intermittent or continuous, may provide health benefits for their patients and prevent mortality.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

      1. Understanding the epidemic. Centers for Disease Control and Prevention. https://www.cdc.gov/drugoverdose/epidemic/index.html. Updated March 21, 2021. Accessed May 3, 2021.

        • Teeters JB
        • Lancaster CL
        • Brown DG
        • Back SE
        Substance use disorders in military veterans: prevalence and treatment challenges.
        Subst Abuse Rehabil. 2017; 8: 69-77https://doi.org/10.2147/SAR.S116720
        • Bohnert AS
        • Ilgen MA
        • Galea S
        • McCarthy JF
        • Blow FC
        Accidental poisoning mortality among patients in the Department of Veterans Affairs Health System.
        Med Care. 2011; 49: 393-396https://doi.org/10.1097/MLR.0b013e318202aa27
        • McCarthy JF
        • Valenstein M
        • Kim HM
        • Ilgen M
        • Zivin K
        • Blow FC
        Suicide mortality among patients receiving care in the Veterans Health Administration health system.
        Am J Epidemiol. 2009; 169: 1033-1038https://doi.org/10.1093/aje/kwp010
        • Baser O
        • Xie L
        • Mardekian J
        • Schaaf D
        • Wang L
        • Joshi AV
        Prevalence of diagnosed opioid abuse and its economic burden in the Veterans Health Administration.
        Pain Pract. 2014; 14: 437-445https://doi.org/10.1111/papr.12097
        • Bachhuber MA
        • Roberts CB
        • Metraux S
        • Montgomery AE
        Screening for homelessness among individuals initiating medication-assisted treatment for opioid use disorder in the Veterans Health Administration.
        J Opioid Manag. 2015; 11: 459-462https://doi.org/10.5055/jom.2015.0298
        • Meshberg-Cohen S
        • Black AC
        • DeViva JC
        • Petrakis IL
        • Rosen MI
        Trauma treatment for veterans in buprenorphine maintenance treatment for opioid use disorder.
        Addict Behav. 2019; 89: 29-34https://doi.org/10.1016/j.addbeh.2018.09.010
        • Kelley ML
        • Bravo AJ
        • Votaw VR
        • Stein E
        • Redman JC
        • Witkiewitz K
        Opioid and sedative misuse among veterans wounded in combat.
        Addict Behav. 2019; 92: 168-172https://doi.org/10.1016/j.addbeh.2018.12.007
        • Webster LR
        • Cochella S
        • Dasgupta N
        • et al.
        An analysis of the root causes for opioid-related overdose deaths in the United States.
        Pain Med. 2011; 12: S26-S35https://doi.org/10.1111/j.1526-4637.2011.01134.x
        • Centers for Disease Control and Prevention (CDC)
        Unintentional poisoning deaths–United States, 1999-2004.
        MMWR Morb Mortal Wkly Rep. 2007; 56: 93-96
      2. Rural access to health care services request for Information. Health Resources and Services Administration. https://www.hrsa.gov/rural-health/rfi-rural-health-care-access. Updated January 2021. Accessed August 31, 2020.

        • UNC The Cecil G. Sheps Center for Health Services Research. NC Rural Health Research Program
        Rural Health Snapshot (2017).
        UNC The Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC2017 (Published May)
        • Wilder CM
        • Miller SC
        • Tiffany E
        • Winhusen T
        • Winstanley EL
        • Stein MD
        Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain.
        J Addict Dis. 2016; 35: 42-51https://doi.org/10.1080/10550887.2016.1107264
        • Gordon J
        • Volkow N
        Suicide deaths are a major component of the opioid crisis that must be addressed.
        National Institute of Mental Health, Bethesda, MD2019 (Published September 19)
        • Hedegaard H
        • Curtin SC
        • Warner M
        Suicide mortality in the United States, 1999–2017.
        National Center for Health Statistics, Hyattsville, MD2018 (Published November)
      3. Office of Public and Intergovernmental Affairs: chapter 1 health care benefits.
        U.S. Department of Veterans Affairs, 2018 (Updated June 20)
        • Substance Abuse and Mental Health Services Administration
        Medications for opioid use disorder for healthcare and addiction professionals, policymakers, patients, and families: treatment improvement protocol TIP 63.
        Substance Abuse and Mental Health Services Administration, Rockville, MD2018 (Published)
      4. MAT Medication, counseling, and related conditions. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions. Accessed February 19, 2019.

        • Timko C
        • Schultz NR
        • Cucciare MA
        • Vittorio L
        • Garrison-Diehn C
        Retention in medication-assisted treatment for opiate dependence: a systematic review.
        J Addict Dis. 2016; 35: 22-35https://doi.org/10.1080/10550887.2016.1100960
        • Ma J
        • Bao YP
        • Wang RJ
        • et al.
        Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
        Mol Psychiatry. 2019; 24: 1868-1883https://doi.org/10.1038/s41380-018-0094-5
        • Williams AR
        • Samples H
        • Crystal S
        • Olfson M
        Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder.
        Am J Psychiatry. 2020; 177: 117-124https://doi.org/10.1176/appi.ajp.2019.19060612
        • Davis MP
        • Pasternak G
        • Behm B
        Treating chronic pain: an overview of clinical studies centered on the buprenorphine option.
        Drugs. 2018; 78: 1211-1228https://doi.org/10.1007/s40265-018-0953-z
        • von Elm E
        • Altman DG
        • Egger M
        • Pocock SJ
        • Gøtzsche PC
        • Vandenbroucke JP
        The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
        Lancet. 2007; 370: 1453-1457https://doi.org/10.1016/S0140-6736(07)61602-X
        • Centers for Medicare & Medicaid Services
        Opioid morphine equivalent conversion factors.
        Centers for Medicare & Medicaid Services, Baltimore, MD2015 (Published)
        • Peterson R
        • Gundlapalli AV
        • Metraux S
        • et al.
        Identifying homelessness among veterans using VA administrative data: opportunities to expand detection criteria.
        PLoS One. 2015; 10e0132664https://doi.org/10.1371/journal.pone.0132664
        • Manhapra A
        • Petrakis I
        • Rosenheck R
        Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
        Am J Addict. 2017; 26: 572-580https://doi.org/10.1111/ajad.12553
      5. 2010 Rural−urban commuting area (RUCA) codes.
        Economic Research Service, U.S. Department of Agriculture, 2020 (Updated August 17)
        • Quan H
        • Sundararajan V
        • Halfon P
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139https://doi.org/10.1097/01.mlr.0000182534.19832.83
        • Harris AH
        • Reeder RN
        • Ellerbe L
        • Bowe T
        Are VHA administrative location codes valid indicators of specialty substance use disorder treatment?.
        J Rehabil Res Dev. 2010; 47: 699-708https://doi.org/10.1682/jrrd.2009.07.0106
        • Centers for Disease Control (CDC)
        Operational criteria for determining suicide.
        MMWR Morb Mortal Wkly Rep. 1988; 37: 773-780
        • Defense Suicide Prevention Office (DSPO)
        The Suicide Data Repository (SDR) fact sheet.
        Defense Suicide Prevention Office (DSPO), 2020 (Alexandria, VA.) (Published)
        • Hernán MA
        The hazards of hazard ratios.
        Epidemiology. 2010; 21 ([published correction appears in Epidemiology. 2011;22(1):134]): 13-15https://doi.org/10.1097/EDE.0b013e3181c1ea43
        • Mathur MB
        • Ding P
        • Riddell CA
        • VanderWeele TJ
        Web site and R package for computing E-values.
        Epidemiology. 2018; 29: e45-e47https://doi.org/10.1097/EDE.0000000000000864
        • VanderWeele TJ
        • Ding P
        Sensitivity analysis in observational research: introducing the e-value.
        Ann Intern Med. 2017; 167: 268-274https://doi.org/10.7326/M16-2607
        • Sordo L
        • Barrio G
        • Bravo MJ
        • et al.
        Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis ofcohort studies.
        BMJ. 2017; 357: j1550https://doi.org/10.1136/bmj.j1550
        • Larochelle MR
        • Bernson D
        • Land T
        • et al.
        Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.
        Ann Intern Med. 2018; 169: 137-145https://doi.org/10.7326/M17-3107
        • Cornish R
        • Macleod J
        • Strang J
        • Vickerman P
        • Hickman M
        Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database.
        BMJ. 2010; 341: c5475https://doi.org/10.1136/bmj.c5475
        • Kimber J
        • Larney S
        • Hickman M
        • Randall D
        • Degenhardt L
        Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study.
        Lancet Psychiatry. 2015; 2: 901-908https://doi.org/10.1016/S2215-0366(15)00366-1
        • Morgan JR
        • Schackman BR
        • Weinstein ZM
        • Walley AY
        • Linas BP
        Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.
        Drug Alcohol Depend. 2019; 200: 34-39https://doi.org/10.1016/j.drugalcdep.2019.02.031
        • Evans E
        • Li L
        • Min J
        • et al.
        Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006−10.
        Addiction. 2015; 110: 996-1005https://doi.org/10.1111/add.12863
        • Cone EJ
        • Gorodetzky CW
        • Yousefnejad D
        • Buchwald WF
        • Johnson RE.
        The metabolism and excretion of buprenorphine in humans.
        Drug Metab Dispos. 1984; 12 (PMID: 6149907. Accessed March 5, 2021): 577-581
        • Pierce M
        • Bird SM
        • Hickman M
        • et al.
        Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England.
        Addiction. 2016; 111: 298-308https://doi.org/10.1111/add.13193
        • Health Resources and Services Administration
        Funding cycle view: Rural Veterans Health Access Program.
        Health Resources and Services Administration, Rockville, MD2018 (Published)
        • Jacobs JC
        • Blonigen DM
        • Kimerling R
        • et al.
        Increasing mental health care access, continuity, and efficiency for veterans through telehealth with video tablets.
        Psychiatr Serv. 2019; 70: 976-982https://doi.org/10.1176/appi.ps.201900104
        • Pearson K
        • Burgess A
        • Gale J
        • Coburn A
        • Hansen A
        Health information exchange: a strategy for improving access for rural veterans in the Maine Flex Rural Veterans Health Access.
        University of Southern Maine, Muskie School of Public Service, Maine Rural Health Research Center, Portland, ME2016 (Published May)
        • Weintraub E
        • Greenblatt AD
        • Chang J
        • Himelhoch S
        • Welsh C
        Expanding access to buprenorphine treatment in rural areas with the use of telemedicine.
        Am J Addict. 2018; 27: 612-617https://doi.org/10.1111/ajad.12805
        • U.S. Department of Veterans Affairs
        • Health Services Research & Development
        VA Telehealth: overview.
        U.S. Department of Veterans Affairs, Washington, DC2018 (Published December)
        • Miller M
        • Barber C
        • Young M
        • Azrael D
        • Mukamal K
        • Lawler E
        Veterans and suicide: a reexamination of the National Death Index-linked National Health Interview Survey.
        Am J Public Health. 2012; 102 (PMID: 2009484. Accessed March 5, 2021): S154-S159https://doi.org/10.2105/AJPH.2011.300409
        • Speechley M
        • Stavraky KM
        The adequacy of suicide statistics for use in epidemiology and public health.
        Can J Public Health. 1991; 82: 38-42
        https://www.jstor.org/stable/41989983
        Date accessed: May 17, 2021